Current Treatment Insights
Understand Today’s Standard of Care, Prepare for Tomorrow
Our treatment landscape assessments map how patients move through existing therapies and how treatment patterns shape market dynamics. Our treatment landscape analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. We also provide the use of treatments by a line of therapy, and their KOL-perceived advantages and disadvantages. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities, and their treatment, including treatment switches, polypharmacy, compliance, and persistence, is conducted.
What We Provide:
- Current Standard of Care (SoC) across 7MM & emerging markets
- Treatment Algorithm Mapping across major markets
- Physician Practice Pattern Insights
- Therapy-Class & Brand-Level Benchmarking
- Efficacy, Safety, Dosing & Differentiation Analysis
- Real-World Utilization Trends (switching, persistence, adherence)
- Pipeline vs. Standard-of-Care Gap Analysis
How It Helps You:
- Identify commercial white spaces
- Understand why physicians choose certain therapies (differentiation points)
- Benchmark products vs. competitors
- TPP design
- Refine global and local launch strategies
What Strategic Answers Clients Will Receive:
- What are physicians currently prescribing, and why?
- How do treatment algorithms differ across geographies and clinical settings?
- Which therapies dominate the market, and what factors drive their adoption?
- What are the real-world utilization patterns (switching, adherence, persistence)?
- Where are the gaps, dissatisfaction areas, or pain points with current treatment options?
- How can new therapies position themselves relative to today’s standard of care?
Reports:
Market Outlook and Forecast
Thelansis’s “Microsatellite Stable Metastatic Colorectal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Microsatellite Stable Metastatic Colorectal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Erythropoietic Protoporphyria (EPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erythropoietic Protoporphyria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Neovascular Age-Related Macular Degeneration (nAMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neovascular Age-Related Macular Degeneration treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “PD-1 and PD-L1 Inhibitors Market Outlook, Competitive Landscape, Treatment Utilization, and Market Forecast Report – 2026 To 2036” offers a comprehensive view of competitive positioning, treatment utilization, and revenue potential as these therapies move across multiple lines of therapy and disease indications over the 2026-2036 forecast period across eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Advanced or Recurrent Endometrial Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Recurrent Endometrial Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Market Outlook and Forecast
Thelansis’s “Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Limb-Girdle Muscular Dystrophy Type 2i treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.
